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Abstract: Background: Metabolic syndrome (MetS) increases the risk of cardiovascular disease,
with atherogenic dyslipidemia being a major contributing factor. Methods: A systematic review
was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement to assess whether vitamin D supplementation (VDS) alleviates dyslipidemia in
adults with MetS. Scientific databases (PUBMED, MEDLINE, CINAHL, EMBASE, Cochrane Library,
ClinicalTrials.gov, International Clinical Trials Registry Platform) and the gray literature were searched
for randomized controlled trials of VDS, reporting on blood lipids. A narrative review, meta-analyses,
sensitivity analyses, and appraisal of the risk of bias and overall quality of evidence produced were
conducted. Results: Seven studies were included, and four were meta-analyzed. The risk of bias was
generally low, and the final quality of evidence was low or very low. VDS, whether in high or low dose,
significantly increased endline vitamin D blood levels; did not affect total, low-density, high-density
cholesterol levels, and novel lipid-related biomarkers; yet, significantly increased triglycerides (TG)
levels compared with placebo (MD: 30.67 (95%CI: 4.89–56.45) mg/dL; p = 0.02 for low-dose VDS;
and MD: 27.33 (95%CI: 2.06–52.59) mg/dL; p = 0.03 for high-dose VDS). Pertaining heterogeneity
was high (I2 = 86%; and I2 = 51%, respectively), and some included studies had significantly higher
baseline TG in the intervention arm. The sensitivity analyses revealed robust results. Conclusion:
VDS seems not to affect blood lipids in adults with MetS.
Keywords: vitamin D supplementation; metabolic syndrome; dyslipidemia; cholesterol; triglycerides;
adult; systematic review; meta-analysis

1. Introduction
Metabolic syndrome (MetS) is a conglomeration of cardiometabolic disorders that collectively
increases a person’s risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease
(CVD) [1,2]. Over the last two decades, the number of people diagnosed with MetS has increased
considerably, encompassing 20% to 25% of the adult population and presenting an enormous public
health issue [3,4].
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The precise definition of MetS varies slightly between guidelines issued by expert groups
including the World Health Organization (WHO); the National Cholesterol Education Program
Third Adult Treatment Panel (NCEP ATP III); the International Diabetes Federation (IDF); and the
American Heart Association/National Heart, Lung, and Blood Institute [5]. Yet, the core components
of this syndrome consist of glucose intolerance, hypertension, dyslipidemia—specifically, reduced
high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG), and central obesity [6].
Individuals with MetS are at an increased risk for CVD, with atherogenic dyslipidemia (low HDL-C
and hypertriglyceridemia) being a major underlying cause for its development [7]. Atherogenic
dyslipidemia emerges as the greatest competitor of low-density lipoprotein cholesterol (LDL-C) among
lipid risk factors for CVD [8–10]. Achieving a better understanding of this atherogenic dyslipidemia
and factors associated with it may provide clues and further insight into possible interventions that
may reduce the risk of CVD in this patient population [5,10].
Vitamin D supplementation (VDS) is among those interventions suggested to alleviate atherogenic
dyslipidemia in patients with MetS [11]. Vitamin D is a fat-soluble vitamin that has an integral role
in skeletal and immune system disorders [12], along with numerous metabolic functions, including
glucose homeostasis, insulin regulation of body weight, and a potent modifier of cardiovascular risk [13].
Vitamin D deficiency, or low levels of 25-hydroxyvitamin D, is associated with a higher risk of MetS.
Additionally, suboptimal levels of the vitamin may increase the severity of the syndrome [14,15].
Concentrations of 25-hydroxyvitamin D are lower in patients with MetS compared with those without
it [16], and the prevalence of MetS is reduced by half if individuals have high 25-hydroxyvitamin
D concentrations [17]. Specifically, vitamin D might modulate the atherogenic components of MetS.
A significant inverse relationship has been observed between higher levels of serum 25-hydroxyvitamin
D and hypertriglyceridemia, in addition to a positive association with HDL-C [18–20]. Nevertheless,
some studies report a controversial association between low levels of 25-hydroxyvitamin D and MetS
and its individual components [21,22]. Numerous randomized controlled trials (RCTs) have investigated
the effect of VDS on dyslipidemia among patients with MetS and found conflicting results [16,23,24].
Therefore, the aim of this systematic review and meta-analysis is to summarize the available evidence of
RCTs to establish the impact of VDS on dyslipidemia among adult patients with MetS.
2. Materials and Methods
2.1. Review Design
The review was conducted according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [25] and following a predefined protocol that was registered at the
OSF registries (DOI: 10.17605/OSF.IO/XBJM8). Ethical approval was not required for the current study.
2.2. Criteria for Study Inclusion
This systematic review included randomized controlled trials (RCTs) conducted on adults with
the metabolic syndrome, including an intervention group that received supplementation with vitamin
D and a control group, where dyslipidemia was reported as an outcome.
RCTs supplementing vitamin D3 or D2 in any form to the intervention group, and a placebo or a
lower dose of vitamin D provided to the control group; investigating at least one of the dyslipidemia
components of the metabolic syndrome (Total Cholesterol (TC), LDL-C, HDL-C, or TG) measured in
the fasting state; including adult participants, as defined by the investigators—e.g., aged > 18 years at
baseline, suffering from the metabolic syndrome (irrespective of the definition adopted)—were included.
Only RCTs with a minimum duration of 4 weeks were included to ensure that the intervention had
sufficient time to produce an effect. Additionally, RCTs involving a co-intervention were included if
both arms of the study received the same co-intervention.
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Studies were excluded if they were conducted on healthy participants, or participants with chronic
or acute conditions other than the metabolic syndrome, or participants receiving medication known to
influence vitamin D metabolism.
2.3. Search Strategy
The search strategy considered two key concepts: (1) vitamin D and (2) metabolic syndrome.
For each concept, Medical Subject Headings (MeSH) and keywords were mapped. Search terms
included but were not limited to vitamin D, cholecalciferol, ergocalciferol, or calcidol, combined
with metabolic syndrome. The following databases were searched: PUBMED, MEDLINE, CINAHL,
EMBASE, the Cochrane Library, ClinicalTrials.gov, and the International Clinical Trials Registry
Platform (ICTRP) [26,27]. No language restrictions were applied to the search; however, the timeline
was limited to studies published after the year 1998—when the first definition of the metabolic
syndrome was issued by the World Health Organization [3]—until 31 July 2020. The electronic
search strategy was validated by a medical information specialist and is described in the Supplement.
Bibliographies of included RCTs and relevant reviews were also hand-searched for eligible studies.
2.4. Study Selection
Two pairs of authors screened titles and/or abstracts retrieved by the search and identified studies
that potentially meet the inclusion criteria outlined above. The two pairs then reviewed the full texts of
potentially eligible studies independently and in duplicate, and assessed them for eligibility. To ensure
the validity of the study selection process, a calibration exercise was first conducted. Disagreements
were solved through consensus or with the help of a third reviewer.
2.5. Data Extraction
Two pairs of authors extracted data from eligible studies independently and in duplicate using
a data extraction form. A calibration exercise was first conducted to ensure the validity of the data
extraction process. For all eligible records, the authors recorded characteristics of the study, details of the
population, interventions (type, form, and the dose of vitamin D in experimental groups, comparator,
and duration), outcomes assessed, as well the main findings. Serum 25OHD was converted to nmol/L,
if it was reported as ng/mL by multiplying by a factor of 2.496. Serum TC, LDL-C, HDL-C, and TG
were converted to mmol/, if they were reported as mg/dL, using the respective multiplication factors:
0.0259 for TC, LDL-C, and HDL-C, and 0.0113 for TG.
2.6. Quality Assessment
Two pairs of authors assessed independently and in duplicate the risk of bias of included RCTs
following the Cochrane criteria (sequence generation, allocation concealment, blinding of participants
and outcome assessors, incomplete outcome data, and selective outcome reporting) [28]. Each potential
source of bias was graded as low, high, or unclear risk. Disagreements were solved through consensus
or with the help of a third reviewer.
The overall quality of the evidence generated by the meta-analysis was assessed according to
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology
(high risk of bias, imprecision, indirectness, heterogeneity, and publication bias). The evidence was
presented using GRADE Evidence Profiles developed in the GRADEpro software [29].
2.7. Data Synthesis
When a meta-analysis was not possible, a narrative review of the findings was performed.
Meta-analyses were conducted when participants, treatments, and the outcomes were similar enough
to allow pooling. Standard meta-analyses comparing VDS with no supplementation in patients
with metabolic syndrome were performed using RevMan version 5.3 (The Cochrane Collaboration,
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The Nordic Cochrane Centre). A fixed-effects model was used when analyzing two studies and
a random-effects model when analyzing more than two studies. The results were reported on
2020, 12,
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3.2. Characteristics of Included Studies
Characteristics of included studies are given in Table 1. The studies by Makariou [30–32] were
conducted on the same sample, but reported on different outcomes in three different manuscripts.
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Three of the studies were conducted in Greece [30–32], two in Iran [33,34], one in Thailand [33] and
one in China [34]. The number of trial participants varied from 50 to 123, and a mean age ranging
between 40 and 65 years. All of the studies were conducted on participants suffering from the MetS,
diagnosed either by the NCEP-ATP III [30–34], the IDF [35], or the joint interim statement between
several major organizations [36]. The follow-up period varied from 8 weeks [33] to 1 year [34].
In three studies, the intervention consisted of vitamin D3 supplementation with dietary
intervention [30–32], one study used vitamin D (without specifying its type) supplementation with
physical activity [35], two studies supplemented only with vitamin D3 [34,36], and one study
supplemented with vitamin D2 [33]. The average daily dose of VDS ranged from 700 IU [34] to
7142.85 IU [36], whereby four studies were supplemented with 2000 IU per day [30–32,35]. Four RCTs
were placebo-controlled [33–36], and in the other three RCTs [30–32], the comparator was dietary
intervention according to the NCEP-ATP III guidelines. Only Yin et al. [34] included a co-intervention
in the form of calcium supplementation.
As for study outcomes detailed in Table 2, TC, TG, HDL-C, and LDL-C were analyzed in four
studies [30,33,35,36]. In addition, Salekzamani et al. [36] assessed TG/HDL-C and LDL-C/HDL-C.
Yin et al. [34] analyzed TG, HDL-C, and LDL-C only. Novel lipid-related biomarkers were also
assessed in Makariou et al. [30]—i.e., apo A1 and Apo B; Makariou et al. [32]—i.e., oxidized-LDL,
oxidized-LDL/LDL, and oxidized LDL/ApoB; Makariou et al. [31]—i.e., sLDL-C and mean LDL size.
3.3. Assessment of Risk of Bias
The assessment of the risk of bias of included studies is presented in Figure 2. The quality of
the RCTs design and reporting was low in general and varied across studies. Random allocation
of participants was reported in the three studies by Makariou et al. [30–32] and in the study by
Salekzamani et al. [36], and was unclear in the other three studies [33–35]. Only Salekzamani et al. [36]
gave sufficient detail to ascertain adequate allocation concealment, while this was unclear in the other
studies [30–35]. Blinding of participants was impossible in the studies by Makariou et al. [30–32],
reflecting a high risk of bias, and was guaranteed only in the study by Salekzamani et al. [36] and
Wongwiwatthananukit et al. [33]. All trials had adequate blinding of outcome assessment, complete
outcome data, and low selective reporting bias.
3.4. Results of Included Studies
Table 2 describes the findings from the included studies. All the included studies [30–36] reported
a significant increase in vitamin D status in the intervention groups at endline. Regarding end-point
values of lipid parameters, Makariou et al. [30], Wongwiwatthananukit et al. [33], and Yin et al. [34]
found no significant differences in TC, TG, LDL-C, and HDL-C between the compared groups.
In Farag et al. [35], TG at baseline was significantly higher in the vitamin D group compared with the
other groups, and HDL-C was significantly higher in the vitamin D + physical activity group compared
with the other groups, which hindered the direct comparison between the three groups at endline.
The authors reported that endline TC was significantly lower in the vitamin D group compared with
the other groups, LDL-C was significantly lower in the vitamin D group compared with the placebo
group, and HDL-C was significantly higher in the vitamin D + physical activity group compared
with the other groups. Regarding within-group changes, there was a greater significant decrease in
TC and LDL-C in the vitamin D + physical activity group compared with the placebo group; and no
other differences in changes in TG and HDL-C between baseline and endline were noted in the three
groups [35]. Additionally, in Salekzamani et al. [36], at baseline, TG and TG/HDL-C were significantly
higher in the intervention group than the control group. At endline, the authors reported a greater
decrease in TG and TG/HDL-C in the vitamin D group compared with the C group, but did not find
significant changes in other parameters, namely TC, HDL-C, LDL-C, and LDL-C/HDL-C [36]. Similarly,
no significant changes in novel lipid-related biomarkers were noted with VDS in the two studies by
Makariou et al. [31,32].
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3.4. Results of Included Studies
Table 2 describes the findings from the included studies. All the included studies [30–36]
reported a significant increase in vitamin D status in the intervention groups at endline. Regarding
end-point values of lipid parameters, Makariou et al. [30], Wongwiwatthananukit et al. [33], and Yin
et al. [34] found no significant differences in TC, TG, LDL-C, and HDL-C between the compared
groups. In Farag et al. [35], TG at baseline was significantly higher in the vitamin D group compared
with the other groups, and HDL-C was significantly higher in the vitamin D + physical activity group
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Table 1. Characteristics of included studies.
First
Author, year

Study
Design

Farag, 2019
[35]

Parallel
randomized
placebocontrolled
trial

Makariou,
2017 [30]

Prospective,
randomized,
open-label,
blinded
end-point
trial

Makariou,
2019a [32]

Prospective,
randomized,
open-label,
blinded
end-point
trial

Makariou,
2019b [31]

Prospective,
randomized,
open-label,
blinded
end-point
trial

Geographic
Setting/Data
Collection
Time Period

Study Population

Halabja
(Kurdistan
Region of
Iraq)/March to
May

I1: n = 24; I2: n = 21;
C: n = 25 Ethnicity:
NR Mean age (SD):
I1: 40.54 (5.94);
I2: 40.42 (5.89);
C: 42.6 (5.62)%
Male:I1: 33.3%;
I2: 33.3%; C: 52.0%

Greece/March
to September

I: n = 25; C: n = 25
Ethnicity: NR Mean
age (SD): I: 52 (9);
C: 51 (12)%
Male: I: 60%; C: 44%

Greece/March
to September

I: n = 25; C: n = 25
Ethnicity: NR Mean
age (SD): I: 53 (7);
C: 52 (15)%
Males: I: 60%;
C: 40%

Greece/March
to September

I: n = 25; C: n = 25
Ethnicity: NR Mean
age (SD): I: 53 (7);
C: 52 (15)%
Males: I: 60%;
C: 40%

Definition of
Metabolic
Syndrome

Intervention

Dose,
Frequency,
Duration

Daily
Dose
Equivalent

Control

IDF criteria

I1. Vitamin D
without PA
I2. Vitamin D +
PA

I1: 2000 IU,
Daily,
12 weeks
I2: 2000 IU,
Daily,
12 weeks +
30 min of
endurance
PA, Daily

2000 IU

Placebo without
endurance PA

NCEP-ATP III
criteria

Vitamin D3 +
dietary
intervention
according to the
NCEP-ATP III
guidelines

2000 IU

Dietary
intervention
according to
NCEP-ATP III
guidelines

NCEP-ATP III
criteria

Vitamin D3 +
dietary
intervention
according to
NCEP-ATP III
guidelines

2000 IU

Dietary
intervention
according to
NCEP-ATP III
guidelines

NCEP-ATP III
criteria

Vitamin D3 +
dietary
intervention
according to
NCEP-ATP III
guidelines

2000 IU

Dietary
intervention
according to
NCEP-ATP III
guidelines

2000 IU,
Daily,
12 weeks

2000 IU,
Daily,
12 weeks

2000 IU,
Daily,
12 weeks

CoIntervention

Compliance

Drop-Out

None

NR

I1: 20%
I2: 30%
C: 16.66%

None

Compliance with
Vitamin D: NR
Poor compliance
with dietary
instructions in
both groups

0%

None

I: 100%;
poor compliance
with dietary
instructions C:
Poor compliance
with dietary
instructions

0%

None

Compliance with
Vitamin D: NR
Poor
compliancewith
dietary
instructions in
both groups

0%
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Table 1. Cont.
First
Author, year

Study
Design

Geographic
Setting/Data
Collection
Time Period

Randomized
placebocontrolled,
Tabriz,
Salekzamani,
doubleIran/October to
2016 [36]
blind
June
parallel
trial

Study Population

Definition of
Metabolic
Syndrome

Intervention

Dose,
Frequency,
Duration

Daily
Dose
Equivalent

Control

I: n = 35; C: n = 36
Ethnicity: NR Mean
age (SD):
40.49 (5.04)%
Males: 49% (data
per group: NR)

Criteria of the joint
interim statement of
the IDF task force on
epidemiology and
prevention; NHLBI;
AHA; World Heart
Federation;
International
Atherosclerosis
Society;
and International
Association for the
Study of Obesity

Vitamin D3

50,000 IU,
Weekly,
16 weeks

7142.85 IU

Placebo

I1: vitamin D2
I2: vitamin D2

I1: 40,000
IU, Weekly,
8 weeks I2:
20,000 IU,
Weekly,
8 weeks + 1
placebo
capsule,
Weekly,
8 weeks

I1:
5714.28 IU
I2:
2857.14 IU

Placebo

Vitamin D3

700 IU,
Daily,
1 year

I1: n = 28; I2: n = 28;
Prospective
C: n = 28 Ethnicity:
randomized,
NR Mean age (SD):
Wongwiwatt double-blind,
Bangkok,
I1: 62.29 (10.63);
hananukit,
doubleThailand/January
I2: 63.61 (13.25);
2013 [33]
dummy,
to September
C: 65.07 (11.31)%
parallel
Male: I1: 53.3%;
trial
I2: 50%; C: 50%

Yin, 2016
[34]

Randomized
placebocontrolled
intervention
trial

Jinan,
North China/
November to
February

I: n = 61; C: n = 62
with vitamin D
deficiency (25(OH)D
< 50 nmol/L)
Ethnicity: Northern
Chinese Mean age
(SD): 49.5 (8.72)%
Male: 54% (data per
group: NR)

NCEP-ATP III
criteria

Updated NCEP-ATP
III criteria for Asian
Americans

700 IU

Placebo

CoIntervention

Compliance

Drop-Out

None

97% in both
groups

I: 12.5%
C: 10%

None

100% in the
3 groups

I1: 6.66%
I2: 6.66%
C: 6.66%

600 mg
elemental
95% in both
Calcium
groups
(CalciumCitrate),
Daily

I: 3.17%
C: 1.58%

I: Intervention; C: Control; NR: Not Reported; SD: Standard Deviation; 25(OH)D: 25-Hydroxyvitamin D; NCEP-ATP: National Cholesterol Education Program Adult Treatment Panel III;
IDF: International Diabetes Federation; NHLBI: National Heart, Lung, and Blood Institute; AHA: American Heart Association; PA: Physical Activity; IU: International Unit.
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Table 2. Outcomes and results of included studies.

First
Author, year

Farag, 2019
[35]

Makariou,
2017 [30]

Assessment
Method:
Vitamin D

25(OH)D:
measured by
immunoassay

25(OH)D:
measured by
enzyme
immunoassay

Assessment
Method:
Dyslipidemia
Outcomes

TC, TG: measured
using enzymatic
colorimetric tests
HDL-C: measured
after precipitation
of the
apolipoprotein B
containing
lipoproteins with
phosphotungistic
acid LDL-C:
calculated from
serum TC, TG and
HDL-C based on
relevant formula

Baseline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Mean (SD)
I1: 26.70 (6.98)
I2: 25.95 (7.98)
C: 30.20 (9.73)

TC, TG, HDL-C:
measured
enzymatically
LDL-C: calculated
median (min–max)
by the Friedewald
I: 39.93 (7.48–87.36)
equation (when
C: 24.96 (9.98–117.84)
TG < 350 mg/dl)
ApoA1, ApoB:
measured by
immunonephelometry

Endline Dyslipidemia
Outcomes HDL-C, LDL-C:
mmol/L * 38.67 = mg/dL
TG: mmol/L *
88.57 = mg/dL

Conclusion

Mean (SD)
I1: 57.90 (12.23)
I2: 72.38 (13.72)
C: 31.44 (9.98)

TC mean (SD) (mg/dL)
I1: 173.5 (60.8)
I2: 194.7 (32.2)
C: 185.9 (39)
HDL-C mean (SD) (mg/dL)
I1: 34.9 (17.3)
I2: 40.9 (14.4)
C: 30.04 (8.5)
LDL-C mean (SD) (mg/dL)
I1: 120.7 (64.4)
I2: 149.6 (35.8)
C: 150.4 (39.8)
TG mean (SD) (mg/dL)
I1: 229.3 (113.8)
I2: 184.5 (98.5)
C: 174.4 (43)

TC mean(SD) (mg/dL)
I1: 160.5(33.4)
I2: 181.7(31.3)
C: 196.8(39.4)
HDL-C mean (SD) (mg/dL)
I1: 33.7 (10.6)
I2: 39 (10)
C: 31.8 (7)
LDL-C mean (SD) (mg/dL)
I1: 107(36.6)
I2: 138.3(31.4)
C: 158.8(39)
TG mean (SD) (mg/dL)
I1: 233.8 (97)
I2: 178.1 (80.8)
C: 158.6 (35.4)

At baseline, TG was significantly
higher in the I1 compared with the
other groups; and HDL-C was
significantly higher in the I2 group
compared with the other groups
There were NS differences in other
study parameters between groups
At endline, 25(OH)D was significantly
higher in the I1 and I2 group compared
with the C group
TC was significantly lower in the
I1 group compared with the
other groups
LDL-C was significantly lower in the
I1 group compared with the C group
HDL-C was significantly higher in
I2 compared with the other groups
Greater significant decrease in TC and
LDL-C in I2 compared with the
C group
There were NS differences in changes
in TG and HDL-C between baseline
and endline in the 3 groups

median (min–max)
I: 76.37 (20.96–167.23)
C: 32.44 (8.73–92.35)

TC mean (SD) (mg/dL)
I: 219 (36)
C: 231 (34)
HDL-C mean (SD) (mg/dL)
I: 48 (10)
C: 50 (9)
LDL-C mean (SD) (mg/dL)
I: 140 (35)
C: 147 (26)
TG median (min–max)
(mg/dL)
I: 150 (56–336)
C: 146 (84–339)
Apo A1 mean (SD) (mg/dL)
I: 136 (26)
C: 143 (13)
Apo B mean (SD) (mg/dL)
I: 92 (25)
C: 107 (16)

TC mean (SD) (mg/dL)
I: 224 (37)
C: 2232 (42)
HDL-C mean (SD) (mg/dL)
I: 49 (9)
C: 49 (10)
LDL-C mean (SD) (mg/dL)
I: 145 (34)
C: 152 (37)
TG median (min-max)
(mg/dL)
I: 136 (46–261)
C: 131 (73–307)
Apo A1, ApoB: NR

Endline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Baseline Dyslipidemia
Outcomes HDL-C, LDL-C:
mmol/L * 38.67 = mg/dL
TG: mmol/L
* 88.57 = mg/dL

At baseline, there were NS differences
in study parameters between groups
At endline, 25(OH)D was significantly
higher in the I group compared with
the C group
There were NS differences in lipid
parameters between groups
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Table 2. Cont.

First
Author, year

Makariou,
2019a [32]

Makariou,
2019b [31]

Assessment
Method:
Vitamin D

Assessment
Method:
Dyslipidemia
Outcomes

Baseline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

25(OH)D:
measured by
enzyme
immunoassay

Oxidized-LDL:
measured by a
competitive
enzyme-linked
immunosorbent
assay using a
median (95%CI)
specific murine
I: 40.18 (25.70–61.90)
monoclonar
C: 24.71 (13.72–39.18)
antibody
Oxidized-LDL/LDL:
NR
Oxidized-LDL/ApoB:
NR

25(OH)D:
measured by
enzyme
immunoassay

sdLDL-C:
analyzed
electrophoretically
sdLDL proportion,
mean LDL size:
analyzed using the
methods of the
European Panel
On Low-Density
Lipoprotein
Subclasses

median (min–max)
I: 40.18 (8.23–87.60)
C: 24.71 (9.98–98.84)

Endline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Baseline Dyslipidemia
Outcomes HDL-C, LDL-C:
mmol/L * 38.67 = mg/dL
TG: mmol/L
* 88.57 = mg/dL

Endline Dyslipidemia
Outcomes HDL-C,
LDL-C: mmol/L *
38.67 = mg/dL
TG: mmol/L *
88.57 = mg/dL

Conclusion

median (95%CI)
I: 76.37 (64.14–103.58)
C: 32.94 (19.96–58.65)

Oxidized LDL-C mean (SD)
(95%CI) (U/L)
I: 70.3 (15.2) (64.8–87.6)
C: 67.2 (16.9) (59.2–79.3)
Oxidized LDL-C/LDL-C
mean (SD) (95%CI) (U/mg)
I: 0.05 (0.01) (0.46–0.65)
C: 0.06 (0.008) (0.41–0.58)
Oxidized LDL-C/ApoB
mean(SD) (95%CI) (U/mg)
I: 0.08 (0.04) (0.70–1.08)
C: 0.07 (0.008) (0.57–0.74)

Oxidized LDL-C
mean(SD) (95%CI) (U/L)
I: 75.9(21.2) (67.9–89.9)
C: 67.3(19.3) (56.9–92.5)
Oxidized LDL-C/LDL-C
mean(SD) (95%CI)
(U/mg)
I: 0.05(0.01) (0.46–0.60)
C: 0.06(0.02) (0.42–0.78)
Oxidized LDL-C/ApoB
mean(SD) (95%CI)
(U/mg)
I: 0.07(0.01) (0.69–0.82)
C: 0.08(0.02) (0.66–0.91)

At baseline, Ox-LDL/ApoB (U/mg) was
significantly higher in the C group
compared with the I group
There were NS differences in other study
parameters between groups
At endline, 25(OH)D was significantly
higher in the I group compared with the
C group
There were NS differences in lipid
parameters between groups

median (min–max)
I: 76.37 (20.96–168.72)
C: 32.94 (8.73–91.85)

sdLDL median (min–max)
(mg/dL)
I: 9.0 (0.0–40)
C: 7.0 (0.0–22)
sdLDL proportion mean
(SD) (%)
I: 5.7 (5.2)
C: 3.8 (2.8)
LDL size mean (SD) (nm)
I: 264.8 (6.3)
C: 266.5 (3.9)

sdLDL median
(min-max) (mg/dL)
I: 4.0 (0.0–46)
C: 5.0 (2.0–25)
sdLDL proportion mean
(SD) (%)
I: 4.5 (4.4)
C: 3.3 (2.3)
LDL size mean (SD)
(nm)
I: 266.6 (5.2)
C: 267.0 (3.5)

At baseline, there were NS differences in
study parameters between groups
At endline, 25(OH)D was significantly
higher in the I group compared with the
C group
There were NS difference in lipid
parameters between groups
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Table 2. Cont.

First
Author, year

Assessment
Method:
Vitamin D

Assessment
Method:
Dyslipidemia
Outcomes

TG, TC, LDL-C,
25(OH)D:
HDL-C: measured
Salekzamani,
measured by
enzymatically
2016 [36]
chemiluminescent
TG/HDL-C: NR
immunoassay
LDL/HDL-C: NR

25(OH)D:
Wongwiwatt
measured by
hananukit,
chemiluminescent
2013 [33]
immunoassay

TC, TG, HDL-C,
LDL-C: NR

Baseline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Mean (SD)
I: 16.45 (15.50)
C: 23.47 (21.34)

Mean (SD)
I1: 35.66 (8.36)
I2: 37.63 (7.88)
C: 40.43 (7.46)

Baseline Dyslipidemia
Outcomes HDL-C, LDL-C:
mmol/L * 38.67 = mg/dL
TG: mmol/L
* 88.57 = mg/dL

Endline Dyslipidemia
Outcomes HDL-C,
LDL-C: mmol/L *
38.67 = mg/dL
TG: mmol/L *
88.57 = mg/dL

Conclusion

Mean (SD)
I: 78.38 (21.71)
C: 21.46 (17.74)

TC mean (SD) (mg/dL)
I: 212 (42)
C: 200 (39.27)
HDL-C mean (SD) (mg/dL)
I: 45 (8.08)
C: 45 (10.08)
LDL-C mean (SD) (mg/dL)
I: 114 (33)
C: 117 (28)
TG mean (SD) (mg/dL)
I: 269 (97)
C: 185 (61)
TG/HDL-C mean (SD)
I: 6.05 (2.21)
C: 4.22 (1.64)
LDL-C/HDL-C mean (SD)
I: 2.53 (0.69)
C: 2.57 (0.54)

TC mean (SD) (mg/dL)
I: 203.21 (34.63)
C: 197.14 (33.57)
HDL-C mean (SD)
(mg/dL)
I: 47 ± 6.63
C: 47 ± 8.24
LDL-C mean (SD)
(mg/dL)
I: 106 ± 25
C: 111 ± 29
TG mean(SD) (mg/dL)
I: 242 ± 82
C: 196 ± 72
TG/HDL-C mean (SD)
I: 5.20 ± 1.67
C: 4.37 ± 1.99
LDL-C/HDL-C mean
(SD)
I: 2.27 ± 0.53
C: 2.36 ± 0.64

At baseline, TG and TG/HDL-C were
significantly higher in the I group
compared with the C group
There were NS differences in other study
parameters between groups
At endline, 25(OH)D significantly
increased in the I group and was stable in
the C group
TG and TG/HDL-C had a greater% change
in the I compared with the C group
There were NS differences in other lipid
parameters between groups

Mean (SD)
I1: 75.95 (17.39)
I2: 66.89 (15.89)
C: 47.39 (16.74)

TC mean (SD) (mg/dL)
I1: 180.36 (34.43)
I2: 166.89 (20.95)
C: 174.29 (38.90)
HDL-C mean(SD) (mg/dL)
I1: 53.18(12.46)
I2: 52.36(11.86)
C: 53.43(12.73)
LDL-C mean(SD) (mg/dL)
I1: 107.00(27.46)
I2: 96.68(19.96)
C: 102.50(29.51)
TG mean(SD) (mg/dL)
I1: 139.32(61.26)
I2: 132.29(62.36)
C: 129.46(59.75)

TC mean (SD) (mg/dL)
I1: 182.04 (31.00)
I2: 170.54 (39.83)
C: 175.96 (39.12)
HDL-C mean (SD)
(mg/dL)
I1: 52.54 (13.49)
I2: 50.96 (12.21)
C: 53.46 (11.75)
LDL-C mean (SD)
(mg/dL)
I1: 110.54 (27.47)
I2: 102.96 (35.09)
C: 105.61 (32.31)
TG mean (SD) (mg/dL)
I1: 144.82 (64.07)
I2: 137.79 (53.48)
C: 135.75 (71.40)

At baseline, there were NS differences in
study parameters between groups
At endline, 25(OH)D was significantly
higher in the I1 and I2 groups compared
with the C group
There were NS differences in lipid
parameters between groups

Endline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L
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Table 2. Cont.

First
Author, year

Yin, 2016
[34]

Assessment
Method:
Vitamin D

Assessment
Method:
Dyslipidemia
Outcomes

TG, HDL-C:
measured by
25(OH)D:
enzymatic
measured by
colorimetric assay
double antibody
LDL-C: calculated
radioimmunoassay
using the
Friedwald
equation

Baseline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Mean (SD)
I: 36.44 (5.44)
C: 35.44 (6.36)

Endline 25OHD Level
(nmol/L) ng/mL *
2.496 = nmol/L

Baseline Dyslipidemia
Outcomes HDL-C, LDL-C:
mmol/L * 38.67 = mg/dL
TG: mmol/L
* 88.57 = mg/dL

Endline Dyslipidemia
Outcomes HDL-C,
LDL-C: mmol/L *
38.67 = mg/dL
TG: mmol/L *
88.57 = mg/dL

Conclusion

Mean (SD)
I: 82.61 (10.90)
C: 36.44 (6.98)

HDL-C mean (SD) (mg/dL)
I: 41.38 (3.09)
C: 38.28 (2.70)
LDL-C mean (SD) (mg/dL)
I: 126.06 (9.66)
C: 123.74 (7.73)
TG mean (SD) (mg/dL)
I: 295.84 (60.23)
C: 280.8 (35.43)

HDL-C mean (SD)
(mg/dL)
I: 42.15 (2.70)
C: 40.22 (2.32)
LDL-C mean (SD)
(mg/dL)
I: 122.97 (9.28)
C: 121.42 (8.50)
TG mean (SD) (mg/dL)
I: 250.66 (36.31)
C: 255.1 (19.48)

At baseline, there were NS differences in
study parameters between groups
At endline, 25(OH)D significantly
increased in the I group and was stable in
the C group
There were NS differences in lipid
parameters between groups
Similar results were obtained in the obesity
and non-obesity subgroups

I: Intervention; C: Control; NR: Not Reported; SD: Standard Deviation; 25(OH)D: 25-Hydroxyvitamin D; min: minimum; max: maximum; TC: Total Cholesterol; TG: Triglycerides; HDL-C:
High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; Apo: Apolipoprotein; sdLDL-C: Small Dense Low-Density Lipoprotein Cholesterol; CI: Confidence
Interval; NS: non-significant. *: symbol denoting multiplication.
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3.5. Results of the Meta-Analyses
3.5. Results of the Meta-Analyses
Two of the studies by Makariou et al. [31,32] and that by Yin et al. [34] were not included in the
Two of the studies by Makariou et al. [31,32] and that by Yin et al. [34] were not included in the
meta-analysis; as Makariou et al. [31,32] solely reported on novel lipid-related biomarkers, namely
meta-analysis; as Makariou et al. [31,32] solely reported on novel lipid-related biomarkers, namely
oxidized LDL-C and small-density LDL-C (sdLDL-C), and the study by Yin et al. [34] was conducted
oxidized LDL-C and small-density LDL-C (sdLDL-C), and the study by Yin et al. [34] was conducted
over the period of one year—a duration that is much longer than the other studies. Moreover, in the
over the period of one year—a duration that is much longer than the other studies. Moreover, in the
study by Farag et al. [35], the intervention arm entailing vitamin D + physical activity was excluded
study
by Farag et al. [35], the intervention arm entailing vitamin D + physical activity was excluded
from the meta-analysis since the control arm consisted of administration of placebo only, without
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thestudy
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placebo
only,
physical
activity. In contrast,
by arm
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[30]administration
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both
physical
activity.
In
contrast,
the
study
by
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et
al.
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the
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since both
arms entailed a dietary intervention, allowing it to be canceled out.
arms entailed
dietary
intervention,
it to be canceled
out.
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dailyallowing
dose equivalent
of vitamin
D, two sets of meta-analyses were
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daily
dose
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and the I2 arm
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heterogeneity to none, yet, the sensitivity analyses did not affect the results.
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Figure 3. Meta-analysis of effects of low-dose VDS on LDL-C, HDL-C, TC, and TG. Mean differences
(d*)
for each study are represented by squares, and 95% Confidence Intervals are represented by the lines
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4. Discussion
Vitamin D deficiency is a worldwide public health problem that affects all age groups [37]. It is
Vitamin D deficiency is a worldwide public health problem that affects all age groups [37]. It is
widespread even in sunny countries [38] and in those that have implemented a rigorous VDS strategy
widespread even in sunny countries [38] and in those that have implemented a rigorous VDS strategy
for years [1,2]. The high prevalence of vitamin D deficiency is associated with various factors, including
for years [1,2]. The high prevalence of vitamin D deficiency is associated with various factors,
genetics, skin pigmentation, latitude, air pollution, obesity, in addition to behavioral lifestyle factors,
including genetics, skin pigmentation, latitude, air pollution, obesity, in addition to behavioral
such as sun avoidance, reduced outdoor activities, and use of sunscreen [39].
lifestyle factors, such as sun avoidance, reduced outdoor activities, and use of sunscreen [39].
In parallel, MetS has recently surfaced as a major public health problem and a leading risk
In parallel, MetS has recently surfaced as a major public health problem and a leading risk factor
factor for the progression of T2DM and CVD [8–10]. Specifically, atherogenic dyslipidemia in MetS
for the progression of T2DM and CVD [8–10]. Specifically, atherogenic dyslipidemia in MetS emerged
emerged as a key factor for CVD and a target for future interventions aiming at reducing poor patient
as a key factor for CVD and a target for future interventions aiming at reducing poor patient outcomes
outcomes [7,10]. Patients with MetS were reported to have decreased 25-hydroxyvitamin D levels [40].
[7,10]. Patients with MetS were reported to have decreased 25-hydroxyvitamin D levels [40].
Accordingly, correcting vitamin D deficiency through VDS was suggested to alleviate MetS, specifically
Accordingly, correcting vitamin D deficiency through VDS was suggested to alleviate MetS,
the atherogenic dyslipidemia component of this syndrome [11]. This topic is gaining attention in the
specifically the atherogenic dyslipidemia component of this syndrome [11]. This topic is gaining
research world and is of clinical relevance [41].
attention in the research world and is of clinical relevance [41].
To date, the literature presents conflicting results on the effects of VDS on the dyslipidemia
To date, the literature presents conflicting results on the effects of VDS on the dyslipidemia
component of MetS. Specifically, observational data indicate an inverse association between
component of MetS. Specifically, observational data indicate an inverse association between
hypovitaminosis D and dyslipidemia in patients with MetS [16]. However, our findings indicate
hypovitaminosis D and dyslipidemia in patients with MetS [16]. However, our findings indicate that
that correcting suboptimal vitamin D levels through supplementation was not effective in improving
correcting suboptimal vitamin D levels through supplementation was not effective in improving
dyslipidemia. VDS, whether as D2 or D3, in a high or low dose, for a short or long duration, although
dyslipidemia. VDS, whether as D2 or D3, in a high or low dose, for a short or long duration, although
significantly increased vitamin D blood levels, did not significantly affect TC, LDL-C, and HDL-C
significantly increased vitamin D blood levels, did not significantly affect TC, LDL-C, and HDL-C
levels, nor the levels of novel lipid-related biomarkers. Furthermore, VDS significantly increased
levels, nor the levels of novel lipid-related biomarkers. Furthermore, VDS significantly increased TG
TG levels compared with placebo, although the baseline TG levels of compared arms in two of the
levels compared with placebo, although the baseline TG levels of compared arms in two of the
included studies [35,36] were not comparable, which limits this finding. Our results are similar to
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included studies [35,36] were not comparable, which limits this finding. Our results are similar to
those of other reviews reporting no meaningful changes in blood lipid values secondary to VDS in
healthy, obese, or diabetic subjects [42,43].
The direct or indirect mechanisms through which vitamin D influences the lipid profile remain
unclear [44]. Since the observational and interventional studies have conflicting evidence, it has
been suggested that the association between vitamin D and metabolic disorders may be confounded
by obesity rather than being a causal relationship. Obesity reduces the detectable serum levels of
25-hydroxyvitamin D through the sequestration of vitamin D in body fat tissue or decreased skin
synthesis of vitamin D due to the limited outdoor activity and sun exposure [40,45]. Moreover, chronic
inflammatory processes, which usually present in obese patients, might decrease 25-hydroxyvitamin
D levels [46] and simultaneously affect various metabolic parameters. Accordingly, the relationship
between vitamin D deficiency and poor metabolic profile may be explained by the fact that both of
these factors are prone to cluster in obese subjects. It is thus possible that high vitamin D levels are not
the cause of good health, rather its outcome, since healthy people generally stay outdoors longer and
have better eating habits [42].
Furthermore, the dose, frequency, and duration of supplementation with vitamin D might also
explain the discouraging results of interventional studies. For instance, supplementation for a period
of three months may not be long enough to have a significant effect. The concentration of serum
vitamin D would need to be in the range 100–150 nmol/L for cardiovascular disease protection [47],
whereas the mean endline vitamin D levels in the intervention groups of the studies included in this
review fell well below this level. Furthermore, VDS should be administered on a daily basis to ensure
stable circulating concentrations for optimal functioning of the endocrine system [48]. Therefore,
short treatment durations and bolus doses of some of the included RCTs could explain the null effects.
Finally, it is also possible that vitamin D could provide benefits for cardiometabolic health through
improvement in markers other than the lipid profile, such as in endothelial function [49], or through
its effect on improving serum calcium profile early in the disease course. The latter observation is
suggested by RCTs showing improvements in lipid profile in non-lean healthy subjects with low
dietary calcium intake following vitamin D and calcium supplementation [50].
It is worthy to note that, to date, there is no consensus on the most suitable approach to correct
vitamin D deficiency, and we lack information on the form, dose, frequency, and duration of vitamin D
intervention that would be required to improve the metabolic components of MetS.
Multiple determinants may affect vitamin D status including genetic variation which could
have a clinically important impact on response to VDS treatment among different individuals with
identical doses [51,52]. For a better understanding of the regulation of vitamin D metabolism and
its relation to dyslipidemia, variants of several genes including VDR which encodes the vitamin D
receptor, DHCR7 which encodes the enzyme 7-dehydrocholesterol reductase, CYP2R1 which encodes
the hepatic enzyme 25- hydroxylase, CYP24A1 which encodes 24-hydroxylase, and GC which encodes
DBP the transporting protein for vitamin D DBP should all be considered [53]. Moreover, it is possible
that single nucleotide polymorphisms (SNPs) in genotypes could modify the optimal vitamin D status
required to reduce MetS disease outcomes [54]. Other confounding factors such as seasonal variation
(vitamin D levels rise in summer and drop in winter) and geographic latitude have an important
impact on vitamin D status and its correlation with health risk assessment [55]. Since the reviewed
RCTs have not examined the genetic predisposition, nor the seasonal effect, it could be misleading
to firmly conclude that VDS had no impact on dyslipidemia among MetS patients and hence further
investigations are still warranted.
5. Strengths and Limitations
To our knowledge, this is the first review to systematically assess the effect of VDS and its effect
on dyslipidemia, specifically in adults with MetS. The main strength of our review is that we included
only RCTs, which generally had a low risk of bias. Another strength is that we conducted this review
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according to a predefined protocol, following standard methods for reporting systematic reviews
(Moher, 2010), and using a comprehensive and sensitive search strategy with multiple databases and
gray literature. We also employed several sensitivity analyses to assess the robustness of our results,
whereby in cases of moderate to substantial heterogeneity, we explored and reported on the potential
causes. However, our findings are limited by the small number of identified studies, their small
sample sizes, and short duration. Furthermore, three of the included studies [32,35,36] started out with
significantly higher baseline lipid levels in the intervention group, which limits the results generated
by this review and pertaining meta-analyses.
6. Conclusions
Physiological mechanisms throughout epidemiological data suggest a link between vitamin D
deficiency and MetS. Yet, we report inconsistent results on the relationship between vitamin D status
and dyslipidemia in adults with MetS, mainly pointing towards a lack of effect, despite improvement
in vitamin D status. Our results should be interpreted with caution given the limited number of
included RCTs, the small sample size, and limited intervention period. It is plausible that potentially
the associations between vitamin D and cardiometabolic health are not causal; this was also suggested
regarding the link between vitamin D and a wide range of acute and other chronic health disorders [56].
Despite the fact that the positive outcome of VDS for improving dyslipidemia among patients with
MetS was weak, this does not eliminate the beneficial effect of vitamin D in this subpopulation of
patients as an anti-inflammatory hormone which mediates muscle strength and homeostasis [57].
The use of vitamin D status for clinical implications has been well established for many diseases
including CVDs [58,59]. Several mendelian randomization studies have supported the protective role
of VDS against some diseases such as MS [60]. Hence, further studies are needed before making any
solid conclusions about the vitamin D status for clinical implications for dyslipidemia in the context of
MetS. Till then, it remains crucial to achieve vitamin D sufficiency in patients with MetS.
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